Do you want to help us learn more about skin cancers with little effort on your part? We would like to collect data from your medical record and use tissues sitting in storage to help us better understand how skin cancers work and find treatments/cures. Contact us today to find out how you can be a part of ground-breaking research!

The purpose of this research study is to deliver 6 months of 1:1 health coaching to cancer patients being treated at UNC Cancer Hospital. This program hopes to improve patient's self-confidence and satisfaction with how they feel and what they are able to do day-to-day. This includes exercising, support for healthy eating, emotional and social needs. Health coaching means you will receive weekly phone calls and emails from a trained coach.

Will you be treated for Locally Advanced Head and Neck Squamous Cell Carcinoma? Have you been cancer free for at least two years after previous treatment? If so, you may eligible to participate in a clinical research trial aimed to measure the level of ctDNA in the blood before and after treatment.

Do you have Peripheral T Cell Lymphoma? Has your cancer come back or did it not get better with the last treatment you were given? If so, you may be eligible to participate in this gene therapy research study to learn more about using your own modified immune cells as possible treatment.

Have you been diagnosed with pancreatic cancer? If so, you may be able to take part in a research study looking at the efficacy of neoadjuvant FOLFIRINOX in subjects with non-metastatic pancreatic cancer.

Have you been diagnosed with multiple myeloma or high-risk smoldering multiple myeloma? If so, you may be able to take part in a research study looking at how drugs used to treat multiple myeloma work.

Do you have Neuroblastoma or Osteosarcoma that has either come back or did not get better with your last treatment? If so, you may be able to take part in a study that will modify your own immune cells to see if it may treat your cancer.

Researchers are studying different doses of a therapy (CD19 CAR T-cells) to find the dose that is both the most effective and the safest for patients with relapsed or refractory B-cell lymphoma.

The purpose of this study is to establish a safe dose of study cells (ATLCAR.CD30.CCR4 and ATLCAR.CD30) to give to patients with CD30+ refractory/relapsed Hodgkin's Lymphoma and Cutaneous T-Cell Lymphoma.

Have you been diagnosed with a plasma cell disorder? You may be able to join a registry to help us learn more about the effects of plasma cell disorders on different aspects of life.